Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03579121 · ClinicalTrials.gov registry record · NA
Genomic Opioid Optimization of Dosing and Selections (GOODS) Study
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 76
- Enrollment target
NCT03579121: Completed NA study, sponsored by Mayo Clinic.
NCT03579121 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 76 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03579121, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 76 participants
- Enrollment target
Study Summary
The researchers are conducting this study to see if pharmacogenomic testing before surgery helps the doctor to choose which medications will work best for the patient.
Interventions
- OTHER Pharmacogenomic (PGx)
- OTHER Review results
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2018-10-12 |
| Est. Completion | 2022-04-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03579121
The ClinicalTrials.gov registry entry for NCT03579121 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pharmacogenomic (PGx) is the first listed.
NCT03579121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03579121 about?
NCT03579121 is a clinical study titled "Genomic Opioid Optimization of Dosing and Selections (GOODS) Study". The researchers are conducting this study to see if pharmacogenomic testing before surgery helps the doctor to choose which medications will work best for the patient.
What is the current status of trial NCT03579121?
This trial is currently completed. It is a NA study. The enrollment target is 76 participants. The study started on 2018-10-12. Estimated completion is 2022-04-01.
What interventions are being tested in trial NCT03579121?
The interventions under investigation include: Pharmacogenomic (PGx) (OTHER), Review results (OTHER).
Who is sponsoring clinical trial NCT03579121?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.